Loading...
Docoh

Exelixis (EXEL)

65 patents

Page 2 of 4
Utility
Heterocyclic Adenosine Receptor Antagonists
23 Sep 21
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein.
Sunghoon Ma, Yong Wang, Wei Xu
Filed: 15 Mar 21
Utility
C-met modulator pharmaceutical compositions
21 Sep 21
Jo Ann Wilson, Khalid Shah
Filed: 20 Dec 19
Utility
Method of preparing fluorine-18 labeled Cabozantinib and its analogs
21 Sep 21
The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
Wei Xu, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
Filed: 31 Jul 15
Utility
C-met modulators and methods of use
21 Sep 21
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion.
Lynne Canne Bannen, Diva Sze-Ming Chan, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Vasu Jammalamadaka, Richard George Khoury, James William Leahy, Morrison B. Mac, Grace Mann, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Craig Stacy Takeuchi, Yong Wang, Wei Xu
Filed: 28 Aug 17
Utility
Method of treating cancer
14 Sep 21
Dana T. Aftab, Frauke Schimmoller
Filed: 26 Sep 18
Utility
Crystalline Solid Forms of Salts of N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, Processes for Making, and Methods of Use
26 Aug 21
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 26 May 18
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
24 Aug 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 9 Feb 21
Utility
CorrectedC-met Modulators and Methods of Use
19 Aug 21
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion.
Lynne Canne Bannen, Diva Sze-Ming Chan, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Vasu Jammalamadaka, Richard George Khoury, James William Leahy, Morrison B. Mac, Grace Mann, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Craig Stacy Takeuchi, Yong Wang, Wei Xu
Filed: 28 Aug 17
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
17 Aug 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 14 Oct 20
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
17 Aug 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 14 Jan 21
Utility
Drug combinations to treat multiple myeloma
20 Jul 21
This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
Dana T. Aftab, Peter Lamb
Filed: 5 Aug 15
Utility
Crystalline Solid Forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use
8 Jul 21
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 25 Mar 21
Utility
Crystalline Solid Forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use
1 Jul 21
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 29 Oct 20
Utility
Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
3 Jun 21
Jo Ann Wilson, Khalid Shah
Filed: 8 Feb 21
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
3 Jun 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 9 Feb 21
Utility
Anti-ror Antibody Constructs
27 May 21
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
Lucas BAILEY, Qufei LI, Malgorzata Agnieszka NOCULA-LUGOWSKA, Bryan GLASER
Filed: 18 Apr 19
Utility
Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
27 May 21
Jo Ann Wilson, Khalid Shah
Filed: 19 Jan 21
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
13 May 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 14 Jan 21
Utility
Compounds for the Treatment of Kinase-Dependent Disorders
11 Feb 21
Lynne Canne Bannen, Minna Bui, Faming Jiang, Kin Tso, Yong Wang, Wei Xu
Filed: 25 Jan 19
Utility
Triple Negative Breast Cancer Treatment Method
4 Feb 21
Disclosed is a method of treating triple negative breast cancer in a human patient, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein the amount of cabozantinib is sufficient to activate the immune system.
Sara M. TOLANEY, Dan G. DUDA
Filed: 18 Apr 17
Patents are sorted by USPTO publication date, most recent first